Statistics

Total Visits

Views
Phase II randomized study of figitumumab plus docetaxel and docetaxel alone with crossover for metastatic castration-resistant prostate cancer26

Select a period of time:

Number of views in the range

Views
Phase II randomized study of figitumumab plus docetaxel and docetaxel alone with crossover for metastatic castration-resistant prostate cancer19

Views

Views
October 20240
November 20240
December 20240
January 20251
February 20252
March 202516
April 20250
Download CSV file
 untranslated
 untranslated

Top country views

Views
Singapore16
United States3
 

Top cities views

Views
Dallas1